Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Active, Astrazeneca, Bristol Myers, Cipla, Fera, Immunitybio, Immunoprecise, Innate, Medivir, Neotx, Pear, Polyphor, Quralis, Tetralogic.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akari, Geron, Greenwich Lifesciences, Mitsubishi Tanabe, Prevail, Puma, Puretech Health, Scyneis, Sellas Life Sciences, Tychan.
The FDA’s vaccine advisory committee voted 17-4 with one abstention Dec. 10 to recommend an emergency use authorization (EUA) for the Pfizer Inc./Biontech SE mRNA vaccine BNT-162b2 to prevent COVID-19 in individuals 16 and older.
Roche Holding AG has revealed a partnership with Moderna Inc. involving the use of the Elecsys Anti-SARS-CoV-2 S antibody test in the latter’s mRNA-1273 vaccine research trials. The news comes shortly after Roche received emergency use authorization from the U.S. FDA for the antibody test.
The U.S. FDA has made it easier for people who want to get tested for COVID-19, granting emergency use authorization (EUA) for direct-to-consumer sales of Laboratory Corp. of America Holdings’ (Labcorp) Pixel COVID-19 test home collection kit. With this latest EUA, any individual 18 years and older can purchase the Pixel test system without a prescription.
Keeping you up to date on recent developments in diagnostics, including: Predicting breast cancer recurrence, Comparing SARS-CoV-2 PCR tests, Paying attention to the little guy in proteomics, Increasing biomarker reproducibility
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Senate passes counterfeit device destruction bill; MHRA posts device compliance dates for Brexit.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advanced Bionics, Advanced Medtech, Laboratory Corporation of America, Oxford Immunotec Global, Recor Medical, Virocule.